Pharmacokinetic Evaluation Of Chronomodulated Esomeprazole Delivery For Improved Night-Time Gerd Managements
Abstract
Gastroesophageal reflux disease (GERD) exhibits a circadian pattern, with symptoms often intensifying during the night due to increased acid secretion and supine posture. Esomeprazole, a proton pump inhibitor (PPI), is widely used for GERD management but shows reduced efficacy when administered conventionally due to its pharmacokinetic limitations and mismatch with nocturnal acid secretion. This study focuses on the pharmacokinetic evaluation of a chronomodulated delivery system for esomeprazole, designed to align drug release with peak night-time acid production for enhanced therapeutic outcomes. The formulation was developed using time-dependent polymeric coatings to achieve delayed and sustained release, initiating drug release approximately 4–6 hours post-administration. In vivo pharmacokinetic studies in animal models revealed significant improvements in key parameters including C_max, T_max, and AUC, with enhanced bioavailability and extended plasma retention time. The chronomodulated system demonstrated superior acid suppression during the critical nocturnal window compared to conventional formulations. These findings suggest that chronotherapeutic delivery of esomeprazole may offer a promising approach to improving night-time GERD management, enhancing patient compliance, and minimizing sleep disturbances caused by reflux episodes. Further clinical validation is recommended to confirm its efficacy in human subjects.
Read the paper
Related studies
- Improving sleep quality leads to better mental health: A meta-analysis of randomised controlled trials
- Tocilizumab in patients with severe COVID-19: a retrospective cohort study
- A new aging measure captures morbidity and mortality risk across diverse subpopulations from NHANES IV: A cohort study
- Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study
- Are noise and air pollution related to the incidence of dementia? A cohort study in London, England
- Long COVID symptoms and duration in SARS-CoV-2 positive children — a nationwide cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.